Setting the relative cost to 3 resulted in a cutoff corresponding to the 63rd percentile of CTLA4 expression, with a sensitivity of 100% and a specificity of 51.5% for breast cancer-specific death. This evidence concerns the gene CTLA4 and breast carcinoma.